secwatch.observer — SEC 8-K summary
======================================

Issuer:     CareDx, Inc. (CDNA)
CIK:        0001217234
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004117
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

CareDx prelim Q4 rev $81.9-82.2M (+4% YoY); FY22 rev ~$321M (+8%); $50M buyback authorized
--------------------------------------------------------------------------------

- Preliminary Q4 2022 revenue $81.9-82.2M vs $79.2M in Q4 2021; testing services rev $64.9-65.2M (down from $68.6M).
- Patient testing volume ~47,700 (+14% YoY), including ~2,300 AlloSure Lung tests.
- Authorized $50M share buyback; cash & equivalents ~$292M with no debt.
- Patient and digital solutions rev $28.8M in FY22 vs $10.3M in FY21, a 180% increase.
- CEO targets adjusted EBITDA profitability in H1 2023; full guidance on Feb 2023 call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1217234/000119312523004117/0001193125-23-004117-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1217234/000119312523004117/d443407d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004117

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer